Mitchell Pitlick, MD
Allergy & Immunology · Omaha, NENPI 1073044574
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 72.1% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $20,859, more than ten times the $24 reported in 2022.
Across 425 payments — averaging $62.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Sanofi$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- CSL Behring$470
- GSK$407
- Genentech USA, Inc.$376
- plus $3K from 25 others
What the payments were for
- Consulting fees$1,4155%
- Speaking & faculty fees$15,44058%
- Food & beverage$9,54236%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 94 | $19,093 |
| Sanofi | 79 | $1,713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $1,412 |
| CSL Behring | 29 | $470 |
| GSK | 36 | $407 |
| Genentech USA, Inc. | 13 | $376 |
| Amgen(2 entities) | 18 | $372 |
| Regeneron Healthcare Solutions, Inc. | 21 | $342 |
| Grifols USA, LLC | 15 | $317 |
| Pharming Healthcare, Inc. | 10 | $295 |
| Novartis | 11 | $245 |
| ARS Pharmaceuticals Operations, Inc. | 15 | $178 |
| Biocryst US Sales Co., LLC | 8 | $161 |
| Hospira, Inc. | 7 | $152 |
| Octapharma USA, Inc. | 5 | $102 |
| LEO Pharma Inc. | 4 | $93 |
| Pfizer | 4 | $93 |
| Hikma Pharmaceuticals USA | 4 | $77 |
| Blueprint Medicines Corporation | 3 | $76 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| AbbVie | 3 | $69 |
| Lilly USA, LLC | 3 | $67 |
| Kaleo, Inc. | 3 | $61 |
| Mylan Specialty L.p. | 3 | $56 |
| Optinose US, Inc. | 2 | $37 |
| Organon | 2 | $34 |
| Ionis Pharmaceuticals, Inc. | 2 | $30 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,477 in reported general payments places this provider in the 75th percentile of 21 allergy & immunology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 13 | $36,681 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $25,636 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,806 |
| Arnuity ElliptaFluticasone Furoate | 19 | $3,525 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $1,760 |
| Ipratropium Bromide | 58 | $1,318 |
| Montelukast Sodium | 46 | $642 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $468 |
| Fluticasone Propionate | 28 | $371 |
| Famotidine | 12 | $185 |
| Prednisone | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $407 | $46,96888 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 allergy & immunology providers in Nebraska.
Other allergy & immunology in Omaha
- James TracyOmaha$104K
- Roger KobayashiOmaha$45K
- James FriedlanderOmaha$22K
- Brett KettelhutOmaha$21K
- Teodoro SeguraOmaha$8K
- Gary KoenigOmaha$4K
- Sara MayOmaha$2K
- Brian KellyOmaha$1K
- Jose Zamora SifuentesOmaha$786
- Joel van de GraaffOmaha$692
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.